Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Gimv

Investor type Private Equity Firm

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Looking for a perfect list of funds?

Get recommendations from our smart algorithm

Get the list
Total investments 176
Average round size
info
The average size of a deal this fund participated in
$21M
Portfolio companies 109
Rounds per year 4.19
Lead investments 49
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.38
Exits 52
Key employees 43
Stages of investment
Early Stage Venture
Late Stage Venture

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Software
  • Therapeutics
Summary

Gimv is the famous VC, which was founded in 1980. The main office of represented VC is situated in the Antwerpen. The fund was located in Europe if to be more exact in Belgium.

The fund has no exact preference in a number of founders of portfolio startups. If startup sums 4 of the founder, the chance for it to be financed is low. Among the various public portfolio startups of the fund, we may underline Neurotech, AgroSavfe, FIRE1 Among the most successful fund investment fields, there are Therapeutics, Enterprise Software. For fund there is a match between the location of its establishment and the land of its numerous investments - Belgium. Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Gimv, startups are often financed by Sofinnova Partners, Novartis Venture Fund, 3i Group. The meaningful sponsors for the fund in investment in the same round are Neomed Management, Andera Partners, VI Partners AG. In the next rounds fund is usually obtained by Sofinnova Partners, Neomed Management, HBM Healthcare Investments AG.

Besides them, we counted 31 critical employees of this fund in our database.

The top activity for fund was in 2013. Despite it in 2019 the fund had an activity. This Gimv works on 3 percentage points more the average amount of lead investments comparing to the other organizations. The fund is generally included in 7-12 deals every year. The usual things for fund are deals in the range of 10 - 50 millions dollars. The higher amount of exits for fund were in 2017. Considering the real fund results, this VC is 12 percentage points more often commits exit comparing to other organizations.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Gimv:
Typical Co-investors
Gimv is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Gimv:

Funds with similar focus

Funds from Belgium
Funds with similar focus located in Belgium:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

JenaValve Technology

Health Care
Medical
Medical Device
$100M31 Aug 2022 Munich, Bavaria, Germany

ImCheck Therapeutics

Biopharma
Biotechnology
Health Care
Life Science
Therapeutics
$113M13 Jun 2022 Marseille, Provence-Alpes-Côte d'Azur, France

ImmunOs Therapeutics

Biotechnology
Drug Discovery
Health Care
Pharmaceutical
$77M07 Jun 2022 Zurich, Switzerland

BioConnection

Biopharma
Manufacturing
22 Apr 2022 -

Precirix

Biotechnology
$94M16 Mar 2022 City of Brussels, Belgium

Ceres

Agriculture
Biotechnology
Farming
Fuel
Renewable Energy
$75M27 Sep 2021 California, United States

Anjarium Biosciences

Biotechnology
Pharmaceutical
$60M15 Sep 2021 Schlieren, Zurich, Switzerland

Topas Therapeutics

Advanced Materials
Biotechnology
Chemical
Chemical Engineering
$21M29 Jul 2021 Germany, Baden-Württemberg, Germany

Klotter

Energy
Industrial Automation
05 Jul 2021 Baden-Wurttemberg, Baden-Württemberg, Germany
News
Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Anjarium Biosciences Raises $61M in Series A Financing

– Anjarium Biosciences AG is a Schliren, Zurich-based biotech company focused on creating and delivering a new class of non-viral gene therapies.
– Series A funding closed at $61m.
– The round was co-led by Abingworth and Gimv, with participation from Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company).
– The new investment will be used to advance the company’s pipeline programs towards clinical development.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Gimv?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: